Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Overview
Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Companies Involved in Therapeutics Development
Addex Therapeutics Ltd
Bristol-Myers Squibb Co
Camino Pharma LLC
Denovo Biopharma LLC
Eli Lilly and Co
Johnson & Johnson
Merck & Co Inc
Noema Pharma AG
Sumitomo Pharma Co Ltd
Taisho Pharmaceutical Holdings Co Ltd
Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Drug Profiles
BMT-133218 - Drug Profile
Product Description
Mechanism Of Action
DSP-3456 - Drug Profile
Product Description
Mechanism Of Action
JNJ-1813 - Drug Profile
Product Description
Mechanism Of Action
History of Events
LY-3020371 - Drug Profile
Product Description
Mechanism Of Action
History of Events
mGlu2 M - Drug Profile
Product Description
Mechanism Of Action
History of Events
NOE-109 - Drug Profile
Product Description
Mechanism Of Action
History of Events
pomaglumetad methionil - Drug Profile
Product Description
Mechanism Of Action
History of Events
SBP-0069330 - Drug Profile
Product Description
Mechanism Of Action
History of Events
SBP-9881 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Agonize Metabotropic Glutamate Receptor 2 for Psychosis - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Antagonize mGlu2 for Anxiety and Depression - Drug Profile
Product Description
Mechanism Of Action
TS-134 - Drug Profile
Product Description
Mechanism Of Action
History of Events
TS-161 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Dormant Products
Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Discontinued Products
Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Product Development Milestones
Featured News & Press Releases
Nov 15, 2021: Addex strategic partner successfully completes Phase 1 in Japan with ADX71149
Aug 25, 2021: Camino Pharma initiates phase 1 study of SBP-9330 in development for the treatment of tobacco use disorder
Jul 01, 2021: Addex, Stanford University and University of Copenhagen Publish mGlu2 Structure in ture Using Addex Allosteric Modulators
Jun 07, 2021: Addex starts phase 2 clinical study of ADX71149 for epilepsy
Jan 21, 2021: Addex ADX71149 receives IND approval to start a phase 2a clinical study in epilepsy
Sep 16, 2020: $11.4 million NIH grant advances drug to treat nicotine addiction
Jun 30, 2020: Camino Pharma receives $920K Small Business Innovation Research (SBIR) grant from the tiol Institute of Mental Health
Jun 16, 2020: Addex mGlu2 PAM program to advance into Epilepsy Phase 2a proof of concept clinical study
Oct 02, 2018: Addex selective mGlu2 PAM ADX71149 included in review highlighting promising investigative drugs for epilepsy
Sep 04, 2018: Addex’s selective mGlu2 PAM ADX71149 shows promise in treating severe panic disorders and PTSD
Feb 27, 2017: Addex’s ADX71149 Anti-Epileptic Effect Highlighted in Scientific Jourl, Epilepsia
Sep 23, 2015: Addex ADX71149 Demonstrates Synergistic Efficacy with Levetiracetam in Preclinical Models of Epilepsy
Feb 07, 2014: Addex Reports Top-line Data from ADX71149 Phase 2a Study in Patients with Major Depressive Disorder with Significant Anxiety Symptoms
Oct 29, 2013: Addex Licensee Completes Enrolment of 120 Patients in a Phase 2 Clinical Trial of ADX71149 for the Treatment of Anxious Depression
Nov 05, 2012: Addex Reports Top-line Data From Successful Phase IIa Clinical Study With ADX71149 In Schizophrenia Patients
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indication, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by Addex Therapeutics Ltd, 2022
Pipeline by Bristol-Myers Squibb Co, 2022
Pipeline by Camino Pharma LLC, 2022
Pipeline by Denovo Biopharma LLC, 2022
Pipeline by Eli Lilly and Co, 2022
Pipeline by Johnson & Johnson, 2022
Pipeline by Merck & Co Inc, 2022
Pipeline by Noema Pharma AG, 2022
Pipeline by Sumitomo Pharma Co Ltd, 2022
Pipeline by Taisho Pharmaceutical Holdings Co Ltd, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Dormant Products, 2022 (Contd..2)
Discontinued Products, 2022